These candidates will be developed using SanegeneBio’s tissue-selective ligand and enhancer assisted delivery (LEAD) technology. The partnership focuses on advancing new therapies that can potentially be administered subcutaneously
The authorisations are granted for Gobivaz in 50 mg/0.5 mL and 100 mg/mL formulations, available in pre-filled syringes and autoinjectors. The medication is indicated for the treatment of
The designation highlights the considerable unmet medical needs of patients with AML and recognises LTI-214’s therapeutic potential as a new treatment for this aggressive form of blood cancer.
Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.